Sagent Pharmaceuticals, Inc. (SGNT) Tops Q2 EPS by 10c

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of $0.09, $0.10 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $69.2 million versus the consensus estimate of $67.14 million.

Sagent Pharmaceuticals, Inc. sees FY2014 revenue of $270-290 million, versus the consensus of $279.07 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
• USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c